GU CONNECT has summarised the highlights of the recent ASCO GU 2018 meeting for you.
Prostate Cancer by Associate Professor of Medicine Tanya Dorff, USC Keck School of Medicine, USA
GU CONNECT has summarised the highlights of the recent ASCO GU 2018 meeting for you.
Prostate Cancer by Associate Professor of Medicine Tanya Dorff, USC Keck School of Medicine, USA
Following a residency at Mt. Sinai Hospital in New York City, Dr Dorff came to LAC + USC Medical Center for her hematology and medical oncology fellowship. She currently heads the Genitourinary group within the Department of Medical Oncology at the City of Hope Comprehensive Cancer Center. In addition to being a devoted clinician and translational researcher, Dr Dorff has authored more than 45 peer reviewed articles as well as 35 review articles/commentaries. Dr Dorff serves as an associate editor for Clinical Genitourinary Cancer and Seminars in Urologic Oncology. She has lectured on prostate and bladder cancer treatment nationally and internationally and has presented her research at national meetings. Current research interests include the effects of fasting on chemotherapy side effects and cancer control and immunotherapy for prostate cancer. She has been the principal investigator for more than a dozen clinical trials, involving targeted therapy and immunotherapy, for genitourinary cancers.
AstraZeneca, Astellas, Exelixis, Janssen and SeaGen.
Optimising precision medicine for improved patient outcomes
A closer look at the evolving treatment landscape
Experts' insights on treatment strategies in ER+ metastatic breast cancer settings
Expert insights on multimodal treatment for intermediate hepatocellular carcinoma (HCC)
Best practices and interpretation of results in lung and ovarian cancer
Medical experts discuss treatment strategies and sequencing after ET + CDK4/6i for ER+/HER2- metastatic breast cancer